Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, Parkinson’s disease, endometriosis*, and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid-to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, Twitter, and Facebook. (*in collaboration with AbbVie)
Additional Resources:
As a member of APNA, the field medical affairs team at Neurocrine Biosciences is pleased to provide educational resources to assist in your clinical assessment of drug-induced abnormal movements. These abnormal movements may be observed in patients in both inpatient and outpatient psych settings. Recognition and appropriate differentiation of drug-induced movement disorders (DIMDs), including akathisia, drug-induced parkinsonism (DIP), dystonia, and tardive dyskinesia (TD) are imperative to appropriate treatment since improper treatment may make DIMDs worse.
Below are links to several literature-supported resources that may assist in developing your assessment skills. If you have additional questions or seek additional information, please reach out to your respective Clinical Practice Liaison.
Resources from Neurocrine Biosciences:
